Nidda Healthcare GmbH
Nidda Healthcare GmbH
- Land: Deutschland
Nachricht vom 01.09.2017 | 07:50
Bain Capital and Cinven announce intention to nominate new CEO and CFO for STADA once new composition of Supervisory Board is effective
DGAP-News: Nidda Healthcare Holding AG / Key word(s): Takeover/Change of Personnel
Frankfurt / Munich, 1 September 2017 - Bain Capital and Cinven announce their intention to nominate Claudio Albrecht as new Chief Executive Officer and Mark Keatley as new Chief Financial Officer of STADA Arzneimittel AG. Prior to this, the current CEO Engelbert Coster Tjeenk Willink and CFO Dr Bernhard Düttmann had announced at the STADA Annual General Meeting that they would be ready to step down from their interim positions before expiry of their contracts following the successful completion of the public takeover by Bain Capital and Cinven. In line with German Corporate Governance, the actual appointment of Claudio Albrecht and Mark Keatley will be decided upon by the Supervisory Board of STADA once its new members have been appointed by Court.
Bain Capital and Cinven thank Mr Tjeenk Willink and Dr Düttmann for their significant contribution and excellent leadership over the past months. In the interest of all stakeholders of STADA, both shareholders will work with the newly composed Supervisory Board of the Company towards a fast transition from the current to the new Executive Board while ensuring continuity. Dr Barthold Piening, Chief Technical Officer of STADA, will remain in his position.
Claudio Albrecht and Mark Keatley both have unique backgrounds in the global generics industry, where they have led highly successful growth strategies at major corporations. Claudio Albrecht was Chief Executive Officer and Chairman of generics company Actavis Group until its sale to Watson in 2012. Under his leadership, Actavis grew its revenues to over EUR 2 billion and expanded its international footprint significantly. Previously, he had been CEO of Ratiopharm Group, having started his career in the generics business of Sandoz.
Mark Keatley served as Chief Financial Officer of Actavis Group until its sale in 2012. He also has strong expertise in managing growth and transformation strategies in the generics industry and beyond. Previously he was CFO of Famar, a European contract manufacturer for the healthcare industry. He has also worked in medical diagnostic services, investment banking and private equity.
Claudio Albrecht and Mark Keatley have most recently worked at Albrecht, Prock & Partners, a global strategy consulting firm with a focus on the pharmaceutical and healthcare industry. Over the past years they have advised on multiple major engagements in the generics and broader healthcare sector, including supporting Bain Capital and Cinven during the due diligence process ahead of the successful takeover offer.
Michael Siefke, Managing Director at Bain Capital and Bruno Schick, Partner at Cinven said: "We are very pleased that Claudio Albrecht and Mark Keatley have decided to join STADA as the new CEO and CFO. With their significant expertise in managing comprehensive global growth and transformation strategies in the generics industry, they are uniquely qualified to lead STADA into the next phase of expansion. It was previously intended that Claudio Albrecht would join the Supervisory Board of STADA alongside the representatives of the new majority shareholders. Cinven and Bain Capital have now asked him to step in as CEO, subject to approval of the Supervisory Board, to lead the process of transition to a privately held company, and we are delighted that he has accepted this role. In due course, we expect him to join the STADA group in a Non-Executive role as originally envisaged once a CEO has been recruited who will lead STADA in the long run. We would also like to thank Engelbert Coster Tjeenk Willink and Dr Bernhard Düttmann for their excellent service to the company, and their readiness to lead a challenging process towards what is now a stable ownership structure and promising future."
For Bain Capital
Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since its founding in 1984. Bain Capital's global team of approximately 220 investment professionals creates value for its portfolio companies through its global platform and depth of expertise in key vertical industries including healthcare, consumer/retail, financial and business services, industrials, and technology, media and telecommunications. Bain Capital has offices in Boston, Chicago, New York, Palo Alto, San Francisco, Dublin, London, Luxembourg, Munich, Melbourne, Mumbai, Hong Kong, Shanghai, Sydney and Tokyo and has made investments in more than 300 companies to date. In addition to private equity, Bain Capital invests across asset classes including credit, public equity and venture capital, managing approximately USD 75 billion in total and leveraging the firm's shared platform to capture opportunities in strategic areas of focus.
For more information, visit www.baincapitalprivateequity.com
Cinven is a leading international private equity firm focused on building world-class European and global companies. Its funds invest in six key sectors: Healthcare, Business Services, Consumer, Financial Services, Industrials, and Technology, Media and Telecommunications (TMT). Cinven has offices in key locations including: Frankfurt, London, Paris, Milan, Madrid, Hong Kong, and New York. Since 1988, Cinven funds have invested in 120 companies worth around EUR90 billion. Today Cinven has more than EUR15 billion in assets under management. Cinven takes a responsible approach towards its portfolio companies, their employees, suppliers, local communities, the environment and society.
For more information, please visit www.cinven.com
Nidda Healthcare GmbH: Bain Capital and Cinven ...
Nidda Healthcare GmbH: Public delisting tender ...
Nidda Healthcare GmbH: Bain Capital Private Eq ...
Tender Offer; <DE0007251803>
Bain Capital and Cinven announce appointment o ...
International School Augsburg (ISA) – erste Schule in Deutschland geht an die Börse
Die International School Augsburg – ISA- gemeinnützige AG geht als erste Schule in Deutschland an die Börse und macht damit erstmals das Thema „Bildung“ unter ESG-Kriterien investierbar. Mit dem geplanten Emissionserlös soll ein Campus-Neubau finanziert werden, um die hohe Nachfrage bedienen zu können. In unserer Researchstudie haben wir die hohe Bedeutung der ISA für den regionalen Wirtschaftsstandort, eine hohe Stabilität der Geschäftsentwicklung sowie hohe Sicherheiten durch vorhandene Sachwerte ermittelt. Das Rating lautet KAUFEN.
Der AKTIONÄR News
25. Februar 18:12 CureVac: Impfstoff-News – Aktie bricht ein
25. Februar 17:23 DAX, MDAX & Co mit Verlusten: Deutsche Bank und Bayer im Fokus, ...
25. Februar 16:20 Carnival: Kreuzfahrt-Comeback in den USA erneut verschoben
25. Februar 16:15 Chart-Check Allianz: Munich Re schiebt Aktie zum Kaufsignal
25. Februar 16:00 HelloFresh: Gründer springt auf den SPAC-Hype auf
News im Fokus
Fresenius Medical Care AG & Co. KGaA veröffentlicht Form 20-F für das Geschäftsjahr 2020
24. Februar 2021, 10:51
Release of Annual Report 2019/2020 and Trading Update/Flash Reporting Q1 2020/2021
26. Februar 2021
Original-Research: Nynomic AG (von Montega AG): Kaufen
25. Februar 2021